Wednesday, May 20, 2026

11 days

GHO Capital and CBC Group to merge into $21B healthcare investor (5)

11 days

Common asthma drug may overcome immunotherapy resistance in cancers (17) hot

Asthma drug revives anti‑tumor immunity in resistant cancers
Mechanisms and meetings on immunotherapy resistance

11 days

Two high‑dose radiotherapy sessions safely treat localized prostate cancer (8)

In Detail Full day, Wednesday, May 20, 2026, Timezone: America/Chicago

GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor

Reynald Castaneda / endpoints - European healthcare investor GHO Capital and asset management firm CBC Group are set to join forces, with the new entity to manage over $21 billion. In a Wednesday release, they said ...

AI Summary: GHO Capital and CBC Group have agreed to combine their healthcare investment platforms to create roughly a $21 billion specialist investor focused on health assets. The tie-up consolidates capital and deal teams to chase larger transactions across care delivery, pharma and tech—because apparently healthcare needed a bigger private-equity behemoth.

#healthcare #pharmaceuticals #mergersandacquisitions #digitalhealth #healthcarefinance #venturecapital

M&A as a Precision Instrument: How an $18B+ Dealmaking Wave Is Rewiring Oncology Against the Patent Cliff

4 days / oncodaily

Opinion: Increased oversight of private equity in health care is needed to protect patients and the physician workforce

5 days / medicalxpress

GHO Capital, CBC Group Combine to Form $21B Healthcare Investment Giant

11 days / medcitynews / Katie Adams

GHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm

11 days / fiercehealthcare

GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor

11 days / endpoints / Reynald Castaneda

Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds

livescience - Scientists found that blocking a protein best known for its role in asthma enhances cancer immunotherapy in preclinical models.

AI Summary: Early studies report that a widely used asthma medication can switch off a tumor immune‑evasion pathway and restore anti‑tumor immunity in models and early human data, improving responses in some hard‑to‑treat cancers including aggressive breast tumours. Researchers call for larger trials to confirm clinical benefit and safety.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials

Asthma drug revives anti‑tumor immunity in resistant cancers (5)
Mechanisms and meetings on immunotherapy resistance (5)
All Other Stories

Asthma drug revives anti‑tumor immunity in resistant cancers

Science news this week: Laotian 'death jar', climate change threatens rice crops, and an asthma drug treats tough cancer

8 days / livescience

Asthma Drug Enhances Immunotherapy Response in Resistant Cancers

10 days / oncodaily

Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds

11 days / livescience

A Common Asthma Drug May Help the Immune System Fight Cancer Again

12 days / discovermagazine

Common asthma drug may turn off tumor 'switch' tied to immunotherapy resistance

12 days / medicalxpress

Mechanisms and meetings on immunotherapy resistance

Overcoming Primary and Acquired Resistance to Immunotherapy in NSCLC

5 days / oncodaily

IASLC’s Hot Topic Meeting on Resistance to Immunotherapy in Thoracic Oncology

6 days / oncodaily

Bringing Leaders in All Parts of the IO Drug Development Ecosystem Together – SITC

7 days / oncodaily

Mitochondria may control immune cell activation and the effectiveness of immunotherapy

9 days / medicalxpress

Tumor microenvironment features may predict immunotherapy response in rare cancers

11 days / medicalxpress

All Other Stories

Evan Garrad: Great Talks on Immunotherapy Combinations on Day 1 at ASCO 2026

46 hrs / oncodaily

Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer

2 days / nature

GraphTME: graph-based framework for predicting immunotherapy response by interpreting tumour microenvironment interactions using spatial transcriptomics

3 days / nature

Breast tumors use sugar coating to evade immunity, opening potential immunotherapy path

4 days / medicalxpress

New drug targets pancreatic cancer immunotherapy resistance

4 days / beckershospitalreview / Ella Jeffries

Cassio Murilo T Hidalgo Filho: Overcoming Primary and Acquired Resistance to Immunotherapy in NSCLC

5 days / oncodaily

Erratum for the Research Article “In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy”

11 days / science

Toronto Rock take NLL Cup with win over Halifax Thunderbirds

Denio Lourenco / citynews - Owen Hiltz and Chris Boushy each had three goals and an assist, Mark Matthews had a goal and three assists, and Nick Rose made 34 saves as the Toronto Rock defeated the Halifax Thunderbirds 12-7 to win the National Lacrosse League championship on Sunday a…

AI Summary: A clinical study shows that delivering just two ablative radiotherapy sessions over eight days achieves effective control of localized prostate cancer without adding side effects, offering a dramatically shorter, patient‑friendly regimen. If adopted more widely, the approach could reduce treatment burden, clinic visits and health‑system costs while maintaining cancer control.

#healthcare #oncology #healthcarefinance #cancerresearch #clinicaltrials

Sushil Beriwal: Siemens Healthineers Lunch Session Advancing Cutting Edge Brachytherapy Techniques

2 days / oncodaily

Local Treatment for Prostate Cancer Recurrence After Radiotherapy

3 days / oncodaily

Does ceramide lipid metabolism affect response to prostate cancer drugs?

5 days / medicalxpress

10 Must-Read Posts In GU Oncology This Week

6 days / oncodaily

Sean Collins: Iodinated Rectal Spacers Improve Bladder Dose Constraints in Prostate SBRT

6 days / oncodaily

David Sher: FASTRACKII Final Results at ESTRO26 in Prostate Cancer